Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Mar / Hyperspectral Disease Diagnosis
Analytical science Clinical care Screening and monitoring Profession

Hyperspectral Disease Diagnosis

Peter’s landmark paper: JT Kwak et al., “Improving prediction of prostate cancer recurrence using chemical imaging”, Scientific Reports 5, Article number: 8758 (2015). PMID: 25737022.

By James Nichols, Ian Cree, Miguel Reyes-Múgica 03/29/2016 1 min read

Share

The diagnosis of cancers at an early stage is critical for the long-term survival of patients. For solid cancers, such as lung, breast and prostate cancer, this is currently accomplished by staining tissue samples with hematoxylin and eosin (H&E) dyes followed by histopathological examination; time to results is typically days rather than hours. Furthermore, diagnoses performed in this way are quite subjective. Indeed, if four histopathologists examine a stained tissue sample, there could be four different diagnoses! Clearly, a technique that is faster, more accurate and less subjective than H&E staining is needed. My paper of choice details a very careful collaborative study of the prediction of prostate cancer recurrence. For at least two decades, vibrational spectroscopists have attempted to demonstrate the feasibility of using infrared spectroscopy in medical diagnosis. In the early studies, a FT-IR microspectrometer equipped with a single-element detector was used in the mapping mode, where spectra were measured sequentially, with the sample being moved in steps of a few micrometers. Although the results showed promise, the time required to acquire enough spectra to fully classify tissue samples was too long. Furthermore, an insufficient number of samples were usually tested, so that any results were rarely statistically significant. As a result, optimism for such measurements was not justified. Hyperspectral imaging achieved by the interface of mercury cadmium telluride array detectors to a standard, continuously scanning FT-IR spectrometer allows thousands of spectra of tissue samples to be measured in a couple of minutes with a spatial resolution of between 1 and 10 μm. The spectrum measured at each pixel can be classified by several different chemometric algorithms (sometimes known as chemical imaging). Several research groups have demonstrated the applicability of such methods in predicting different types of cancer. For example, groups led by Rohit Bhargava at the University of Illinois (USA), Max Diem at Northeastern University (USA) and Nick Stone at Exeter University (UK) have all made remarkable progress in that area.

My paper of choice details the results of a very careful collaborative study of the prediction of prostate cancer recurrence by scientists from the US Center for Interventional Oncology at the National Institutes of Health, the Department of Pathology at the University of Illinois at Chicago, and the Computer Science, Bioengineering, and Electrical and Computer Engineering, departments and Cancer Center of the University of Illinois, Urbana-Champaign. Their results significantly outperformed those found using the most commonly applied approaches – H&E staining with classification using the Kattan nomogram or the Cancer of the Prostate Risk Assessment (CAPRA-S) score. The paper stands out because of the combination of very high-quality spectroscopy and data processing and the collaboration of scientists from different disciplines. The paper described an approach that, in the words of its abstract, “provides a histologic basis to a prediction that identifies chemical and morphological features in the tumor microenvironment that is independent of conventional clinical information, opening the door to similar advances in other solid tumors.” In contrast to magnetic resonance spectroscopy, where the MRI technique was rapidly commercialized and adopted in hospitals worldwide within 10 years of demonstrating its feasibility in the laboratory, the uptake of vibrational spectroscopic techniques for medical diagnosis has been slow. Nonetheless, I believe that, within the next decade, the techniques described in this paper could displace current staining techniques for histopathological analysis – or, at the very least, I expect that they will be used alongside them.

Variations on a Drop by James Nichols

A Paper to Circulate by Ian Cree

Hyperspectral Disease Diagnosis by Peter Griffiths

Diagnosis: Digital by Liron Pantanowitz

Collagen and the Colon by Miguel Reyes-Múgica

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Nichols

James Nichols is Director of Clinical Chemistry and Professor in the Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA

More Articles by James Nichols

Ian Cree

Ian Cree is Head of the World Health Organization Classification of Tumors Group, International Agency for Research on Cancer, Lyon, France.

More Articles by Ian Cree

Miguel Reyes-Múgica

Miguel Reyes-Múgica is Marjory K. Harmer Endowed Chair in Pediatric Pathology, Chief of Pathology and Head of Laboratories, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, USA

More Articles by Miguel Reyes-Múgica

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Opening a Window into Brain Trauma
Analytical science
Opening a Window into Brain Trauma

January 18, 2024

4 min read

Raman spectroscopy shows promise as the first point-of-care diagnostic device for TBI

Could ≠ Should
Analytical science
Could ≠ Should

January 20, 2022

1 min read

The need to prevent the ordering of unnecessary tests

Diamonds Are a Diagnostician’s Best Friend
Analytical science
Diamonds Are a Diagnostician’s Best Friend

February 8, 2022

1 min read

A diagnostic sensor for rapid, cost-effective, and accurate detection of SARS-CoV-2

Hunting the Unknown
Analytical science
Hunting the Unknown

February 22, 2022

1 min read

When it comes to human health, we cannot ignore unknown molecules simply because they present analytical challenges

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.